Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CFSAN program priorities

This article was originally published in The Tan Sheet

Executive Summary

FDA center requests comments on fiscal 2003 program goals in June 21 Federal Register notice. Comments on ongoing broad program objective, new initiatives sought. Center asks which "B" list priorities from fiscal 2002 list should move to "A" status. Industry guidances on supplement regulation/labeling, "Food Security Action Plan," long-awaited supplements GMP reg were among "A" list priorities this year (1"The Tan Sheet" Feb. 4, 2002, p. 14). Ephedra strategy, transmissible spongiform encephalopathies goals were among "B" items. FDA seeks comments by Aug. 20...

You may also be interested in...

GMPs, Food Safety, Industry Guidances Among CFSAN’s 2002 Top Priorities

Industry guidances on dietary supplement regulations and labeling issues are slated to be released by FDA's Center for Food Safety & Applied Nutrition over the next two years

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts